Roughly a third to a half of people with Alzheimer's disease develop psychosis at some point, meaning hallucinations, delusions, or both. There is no medication approved in the United States to treat it.
The trial program most likely to change that just moved further away. Bristol Myers Squibb told investors on Thursday that topline results from its three ADEPT studies, testing the schizophrenia drug Cobenfy in Alzheimer's disease psychosis, will now begin arriving in early 2027 and spread across that year. As recently as April, the company still expected all three to report in 2026.
